Johnson & Johnson announced a landmark settlement estimated at $5.5 billion to resolve tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer. This settlement covers about 76,000 claims, including those consolidated in federal and state courts, and represents nearly all remaining talc-related claims against the company.
J & J's vice president of litigation, Erik Haas, described the claims as 'meritless' but stated that the settlement would provide closure for the company, allowing it to concentrate on developing life-saving medicines and devices. The settlement requires acceptance from 95% of the ovarian cancer claimants before it becomes final.
While J & J expects to pay $3 billion in 2027, the total payout could exceed $7 billion depending on participation in the settlement. This agreement follows a series of courtroom victories for J & J, including a recent ruling that cast doubt on the ability of individual plaintiffs to prove their claims.
The company has consistently denied that its talc products are linked to cancer and ceased selling talc-based baby powder in the U.S. in 2020, switching to a cornstarch alternative. The settlement applies only to existing claims and does not cover future lawsuits, which allows for a quicker payout to current plaintiffs compared to previous bankruptcy proposals.
This resolution could stabilize J & J's financial outlook and restore investor confidence, as it removes a significant legal burden and allows the company to focus on its core business operations